Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Min-Iren to Suspend Use of Diovan at 143 Member Hospitals
August 30, 2013
- JMA, PhRMA to Cosponsor Symposium on National Health Insurance System in September
August 29, 2013
- Insulin Treatment Improves Patients’ QOL, Marital Relationship: Healthy Japan 21 Promotion Forum, Sanofi
August 23, 2013
- Stakeholders Should Discuss Novartis’ Responsibility in the Promotion of Diovan, Large Sales: JMA Vice President
August 19, 2013
- Japanese Wholesalers Fill Role of Social Infrastructure: JPWA Report
August 14, 2013
- JMA Establishes Pharmaceutical Affairs Section to Strengthen Engagement with Generic Drug and Distribution Issues
August 9, 2013
- Kenporen Report Recommends Reference to Measures Taken in UK, France to Further Promote Use of Generics in Japan
August 7, 2013
- ICH to Facilitate Participation of Regulatory Authorities from Non-ICH Regions in Future Activities
July 30, 2013
- Average Cost of Domestic Development Was 48.4 Billion Yen per Drug from 2000-2008: OPIR
July 29, 2013
- Red Cross Hospitals to Share Information on Drug Discount Rates
July 29, 2013
- EFPIA and PhRMA Announce Joint “Principles for Responsible Clinical Trial Data Sharing”
July 26, 2013
- SCJ to Discuss Preventive Measures for Misconduct in Science Research
July 24, 2013
- NPO J-CLEAR Says Diovan Data Manipulated Possibly Outside of Endpoint Committee
July 24, 2013
- JPMA Calls on TPP Member States to Make Drug Pricing Process Transparent
July 22, 2013
- FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
- JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
- Pharmaceutical-Related Companies Should Report Business Results to CSIMC: JMARI Working Paper
July 11, 2013
- Product Names Changed for 10% of New Drugs after NDA Filings: OPIR Survey
July 8, 2013
- JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
- JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…